GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development f… Read more
GENOR BIOPHARMA DL-00002 (67N0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GENOR BIOPHARMA DL-00002 (67N0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GENOR BIOPHARMA DL-00002 - Net Assets Trend (None–None)
This chart illustrates how GENOR BIOPHARMA DL-00002's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GENOR BIOPHARMA DL-00002 (None–None)
The table below shows the annual net assets of GENOR BIOPHARMA DL-00002 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GENOR BIOPHARMA DL-00002's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GENOR BIOPHARMA DL-00002 Competitors by Market Cap
The table below lists competitors of GENOR BIOPHARMA DL-00002 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TCPL Packaging Limited
NSE:TCPLPACK
|
$81.99 Million |
|
iClick Interactive Asia Group
NASDAQ:ICLK
|
$82.01 Million |
|
VisionWave Holdings, Inc. Common Stock
NASDAQ:VWAV
|
$82.02 Million |
|
Montauk Renewables Inc
NASDAQ:MNTK
|
$82.02 Million |
|
Westwater Resources Inc
NYSE MKT:WWR
|
$81.97 Million |
|
DACHA STRATEGIC
F:7DC
|
$81.97 Million |
|
New Asia Construction & Development Corp
TW:2516
|
$81.96 Million |
|
Chant Sincere Co Ltd
TW:6205
|
$81.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENOR BIOPHARMA DL-00002's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GENOR BIOPHARMA DL-00002's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GENOR BIOPHARMA DL-00002 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GENOR BIOPHARMA DL-00002's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENOR BIOPHARMA DL-00002 (67N0) | €- | N/A | N/A | $81.97 Million |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $5.62 Million | -3.29% | 0.10x | $5.16 Million |
| Axonics Inc (0I3) | $482.44 Million | -16.60% | 0.14x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $9.23 Million | -118.16% | 1.79x | $369.68K |
| GIEAG Immobilien AG (2GI) | $68.16 Million | -4.05% | 4.40x | $14.69K |
| 2invest AG (2INV) | $84.50 Million | 65.13% | 0.01x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.18 Trillion | 11.74% | 1.15x | $6.90 Million |
| Eurobattery Minerals AB (5KD) | $57.72 Million | -326.44% | 2.20x | $77.17 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $16.88K |
| SOFTCHOICE CORP. (90Q) | $-27.47 Million | 0.00% | 0.00x | $470.36 Million |